Table 2.
Clinical characteristics and allergy work-up by specific IgE ImmunoCAP® results (cut-off ≥ 0.1 kUA/L) for Spanish and Italian study groups. Statistical comparison shown is between positive and negative ImmunoCAP®.
| Spain | Italy | ||||||
|---|---|---|---|---|---|---|---|
| Positive ImmunoCAP (PG and/or AX) (N = 55) |
Negative ImmunoCAP (PG and AX) (N = 84) |
p 1 | Positive ImmunoCAP (PG and/or AX) (N = 131) |
Negative ImmunoCAP (PG and AX) (N = 119) |
p 1 | ||
| Median (IR) age, years | 46 (34–56) | 45 (35–53) | ns | 48 (35–57) | 53 (38–65) | 0.0205 | |
| Gender, % female | 28/55 (50.9%) | 44/84 (52.4%) | ns | 87/131 (66.4%) | 79/119 (66.4%) | ns | |
| Reaction severity, N° (%) patients |
Grade 1 | 10/55 (18.2%) | 25/84 (29.8%) | ns | 30/131 (22.9%) | 40/119 (33.6%) | ns |
| Grade 2 | 31/55 (56.4%) | 36/84 (42.9%) | ns | 70/131 (53.4%) | 56/119 (47.1%) | ns | |
| Grade 3 | 14/55 (25.5%) | 23/84 (27.4%) | ns | 31/131 (23.7%) | 23/119 (19.3%) | ns | |
| Drug causing allergic reaction, N° (%) patients |
Penicillin | 0/55 (0.0%) | 4/84 (4.76%) | - | 0/131 (0.0%) | 0/119 (0.0%) | - |
| AX/AX-CLV | 55/55 (100.0%) | 79/84 (94.1%) | ns | 126/131 (96.2%) | 113/119 (95.0%) | ns | |
| AMP/BAC | 0/55 (0.0%) | 1/84 (1.2%) | - | 5/131 (3.8%) | 6/119 (5.0%) | ns | |
| Positive N° (%) skin tests |
PPL/BP-OL, MDM/MD | 9/55 (16.4%) | 10/84 (11.9%) | ns | 72/131 (55.0%) | 45/119 (37.8%) | 0.0078 |
| AX | 51/55 (92.7%) | 78/84 (92.9%) | ns | 123/131 (93.9%) | 118/119 (99.2%) | ns | |
| Median (IR) time interval reaction/study, days | 150 (90–300) | 180 (90–330) | ns | 60 (30–120) | 60 (30–180) | ns | |
1 Differences were considered statistically significant if p ≤ 0.05. PG: penicillin G.